IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$3.75
−6.84%Oct 29, 2026, 20:05 UTC
Immuneering reported third-quarter 2026 financial results for the quarter ended September 30, 2026.
Source:Oct 29, 2026, 20:05 UTC
Immuneering said follow-up in its Phase 2 first-line pancreatic cancer trial is being extended because patients are living longer than projected.
Source:Sep 28, 2026, 11:30 UTC
Immuneering presented data at the 2026 AACR Conference on pancreatic cancer supporting the mechanisms of atebimetinib designed to extend survival in pancreatic cancer.
Source:Sep 24, 2026, 11:30 UTC
Immuneering Corporation announced that a trial-in-progress abstract for its Phase 3 MAPKeeper 301 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer was accepted for poster presentation at the ESMO Congress 2026 in Madrid.
Sep 10, 2026, 11:30 UTC
Immuneering Corporation announced it will present a poster on atebimetinib's dual mechanism for extended survival at the AACR Conference on Pancreatic Cancer taking place September 25-28, 2026, in San Diego.
Source:Aug 5, 2026, 11:30 UTC
Immuneering Corporation reported its financial results for the second quarter ended June 30, 2026, ending with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029.
Source:Jun 15, 2026, 11:55 UTC
Immuneering Corporation appointed Andrew Gengos as Chief Financial Officer, effective July 16.
Source:Jun 12, 2026, 14:51 UTC
Immuneering (IMRX) began dosing the first patient in a pivotal Phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Source:Jun 11, 2026, 11:30 UTC
Immuneering Corporation dosed the first patient in its pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP for first-line pancreatic cancer.
Source:Jun 1, 2026, 11:30 UTC
Immuneering presented clinical data for atebimetinib plus chemotherapy in first-line pancreatic cancer at ASCO.
Source: